Brennan leaves AstraZeneca, quarterly sales down 11%

Share this article:
AstraZeneca CEO David Brennan
AstraZeneca CEO David Brennan
After announcing round after round of layoffs, AstraZeneca CEO David Brennan announced Thursday that he, too, was joining the ranks of the unemployed. Brennan's resignation goes into effect June 1. His announcement came alongside ugly first quarter results which showed the oncoming pain of a very steep patent cliff -- sales were $7.3 billion for the quarter ended March 31, an 11% drop over the same period last year. CFO Simon Lowth blamed 8 percentage points of that loss on generics, and said that this storyline will remain a “dominant feature of our revenue profile for the year.”

Sales of acid reflux drug Nexium fell 18% for the quarter, to $953 million for the same period last year. US sales took an 11% hit due to a major drop in low-margin Medicaid prescriptions, and generics triggered a 53% drop in Western Europe sales.

Breast cancer drug Arimidex saw sales fall 39%, to $144 million compared to the same period the year before, while sales for anti-psychotic drug Seroquel IR fell 25%, to $754 million, from $1 billion for the same period last year. The drug's hotly-contested XR version saw sales jump 14%, to $384 million for the quarter, compared to the same period last year.

The 2% increase in Crestor sales reflected flat US sales, at $685 million, tempering a 3% increase in international sales for the same period last year.

Lowth will become interim CEO when Brennan steps down in June after six years at the helm of the company. He oversaw three rounds of major staff cuts, the most recent of which, in February, marked 7,300 more jobs for elimination. The company said these would save $1.6 billion annually by 2014. Layoffs that began in 2010 are projected to save the company $1.9 billion in by the end of 2014.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...